Freeline Therapeutics Back to portfolio


Blood cells in a blood vessel

SEM of blood corpuscles in clot.

Royal Free

Hepatocyte

Blood clot forming over a wound

Timeline

March 2014
First meeting between UCL, Prof Amit Nathwani and Syncona, as part of Syncona’s systematic review of gene therapy opportunities.
H2 2014
Syncona engages in deep due diligence into the field of systemic gene therapy and develops the company’s strategy together with founder Prof Amit Nathwani.
May 2015
Syncona founds Freeline Therapeutics with a £25m Series A financing.
May 2015 to Jan 2016
Syncona recruits Freeline’s management team including Chief Development Officer, Chief Technology Officer and SVP Head of Clinical and Regulatory
Aug 2015
Freeline acquires gene therapy manufacturing platform from Rentschler Biotechnologie and recruits experienced team into Munich subsidiary.
Q1 2016
Freeline’s Munich manufacturing capability fully commissioned and operational.

Company Details

Description

Gene therapy for blood disorders

Fully diluted ownership

74%

Value of Syncona holding

£18.0m

% of nav

2.1%

Description

Freeline Therapeutics is a biopharmaceutical company based at the UCLB Royal Free London Hospital focused on the development of liver-directed gene therapies.

Gene therapy is based on technology that delivers a working copy of a faulty gene directly to the target organ. Once delivered, the gene produces a correct form of the missing protein and has the potential to cure the disease.

Freeline’s most advanced program is a treatment for haemophilia B, a rare disorder that causes painful, crippling bleeding in patients’ joints.

There are several genetic diseases that are treated chronically with enzyme replacement therapy (ERT).

Freeline’s technology could replace ERT in a number of these diseases, with a single injection providing the possibility of long-term disease modification.

CEO

Jan Thirkettle

Syncona Representatives
  • Chris Hollowood
  • Dominic Schmidt
CSO
  • Prof. Amit Nathwani